Loading
HKSEHealthcareBiotechnology
Latest quote
HK$27.40
−HK$1.44 · -4.99%
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Latest quote
HK$27.40
−HK$1.44 · -4.99%
Regular session · HKT · Market data may be delayed.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Day range
Current HK$27.40
52-week range
Current HK$27.40
Regular session · HKT · Market data may be delayed.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Day range
Current HK$27.40
52-week range
Current HK$27.40
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | 25.69B CNY | 17.69B CNY | 13.93B CNY | 12.92B CNY | 12.92B CNY |
| Cost of goods sold | 24.31B CNY | 16.46B CNY | 12.68B CNY | 11.7B CNY | 11.72B CNY |
| Gross profit | 1.38B CNY | 1.23B CNY | 1.26B CNY | 1.22B CNY | 1.2B CNY |
| Selling, general, and administrative | 554.02M CNY | 474.04M CNY | 447.42M CNY | 426.48M CNY | 429.24M CNY |
| Operating expenses | 307.29M CNY | 229.45M CNY | 221.13M CNY | 223.22M CNY | 257.54M CNY |
| Interest income | 50.22M CNY | 27.29M CNY | 19.38M CNY | 21.27M CNY | 25.9M CNY |
| Interest expense | 306.06M CNY | 275.33M CNY | 247.53M CNY | 309.08M CNY | 193.64M CNY |
| Depreciation and amortization | — | 794.25M CNY | 764.71M CNY | 697.51M CNY | 595.2M CNY |
| Operating income | 1.2B CNY | 770.54M CNY | 759.37M CNY | 809.02M CNY | 855.84M CNY |
| Net income | 769.11M CNY | 616.58M CNY | 668.76M CNY | 554.39M CNY | 819.6M CNY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.0246
2022 complete year-42.7% since 2018
HK$0.0429
2,018
HK$0.0227
2,019
HK$0.0274
2,020
HK$0.0339
2,021
HK$0.0246
2,022
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 15, 2022 | HK$0.0246Annual | — | — |
Dividend | Jun 16, 2021 | HK$0.0339Annual | — | — |
Dividend | Jun 17, 2020 | HK$0.0274Annual | Jun 18, 2020 | Jul 31, 2020 |
Dividend | Jun 19, 2019 | HK$0.0227Annual | Jun 20, 2019 | Jul 31, 2019 |
Dividend | Jun 20, 2018 | HK$0.0429Annual | Jun 21, 2018 | Jul 31, 2018 |
Dividend | Jun 20, 2017 | HK$0.0459Annual | Jun 21, 2017 | Jul 31, 2017 |
Ex-dividend Jun 15, 2022
HK$0.0246
Annual
Ex-dividend Jun 16, 2021
HK$0.0339
Annual
Ex-dividend Jun 17, 2020
HK$0.0274
Annual
Record Jun 18, 2020 · Payment Jul 31, 2020
Ex-dividend Jun 19, 2019
HK$0.0227
Annual
Record Jun 20, 2019 · Payment Jul 31, 2019
Ex-dividend Jun 20, 2018
HK$0.0429
Annual
Record Jun 21, 2018 · Payment Jul 31, 2018
Ex-dividend Jun 20, 2017
HK$0.0459
Annual
Record Jun 21, 2017 · Payment Jul 31, 2017
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
